4.8 Article

Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform

期刊

NUCLEIC ACIDS RESEARCH
卷 44, 期 9, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkw089

关键词

-

资金

  1. Deutsche Forschungsgemeinschaft [CRC992, CRC 850, CRC 746, Schu688/12-1]
  2. European Research Council [ERC AdGrant] [322844]
  3. ARUK [20522]
  4. Rosetrees Trust
  5. NIHR BRU
  6. SGC
  7. AbbVie [1097737]
  8. Bayer
  9. Boehringer Ingelheim
  10. Canada Foundation for Innovation
  11. Canadian Institutes for Health Research
  12. Genome Canada
  13. GlaxoSmithKline
  14. Janssen
  15. Lilly Canada
  16. Novartis Reserach Foundation
  17. Ontario Ministry of Economic Development and Innovation
  18. Pfizer
  19. Takeda
  20. Wellcome Trust [092809/Z/10/Z]
  21. European Social Fund [VP1-3.1.-SMM-07-K-02-009]
  22. U.S. National Institutes of Health [R01GM103893]
  23. COST action CM1406 (Epigenetic Chemical Biology EPICHEMBIO)
  24. European Research Council (ERC) [322844] Funding Source: European Research Council (ERC)
  25. Versus Arthritis [20522] Funding Source: researchfish

向作者/读者索取更多资源

Epigenetic modifications of histone tails play an essential role in the regulation of eukaryotic transcription. Writer and eraser enzymes establish and maintain the epigenetic code by creating or removing posttranslational marks. Specific binding proteins, called readers, recognize the modifications and mediate epigenetic signalling. Here, we present a versatile assay platform for the investigation of the interaction between methyl lysine readers and their ligands. This can be utilized for the screening of small-molecule inhibitors of such protein-protein interactions and the detailed characterization of the inhibition. Our platform is constructed in a modular way consisting of orthogonal in vitro binding assays for ligand screening and verification of initial hits and biophysical, label-free techniques for further kinetic characterization of confirmed ligands. A stability assay for the investigation of target engagement in a cellular context complements the platform. We applied the complete evaluation chain to the Tudor domain containing protein Spindlin1 and established the in vitro test systems for the double Tudor domain of the histone demethylase JMJD2C. We finally conducted an exploratory screen for inhibitors of the interaction between Spindlin1 and H3K4me3 and identified A366 as the first nanomolar small-molecule ligand of a Tudor domain containing methyl lysine reader.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据